39 research outputs found
A strategy for integrating essential three-dimensional microphysiological systems of human organs for realistic anticancer drug screening
Cancer is one of the leading causes of morbidity and mortality around the world. Despite some success, traditional anticancer drugs developed to reduce tumor growth face important limitations primarily due to undesirable bone marrow and cardiovascular toxicity. Many drugs fail in clinical development after showing promise in preclinical trials, suggesting that the available in vitro and animal models are poor predictors of drug efficacy and toxicity in humans. Thus, novel models that more accurately mimic the biology of human organs are necessary for high-throughput drug screening. Three-dimensional (3D) microphysiological systems can utilize induced pluripotent stem cell technology, tissue engineering, and microfabrication techniques to develop tissue models of human tumors, cardiac muscle, and bone marrow on the order of 1 mm3 in size. A functional network of human capillaries and microvessels to overcome diffusion limitations in nutrient delivery and waste removal can also nourish the 3D microphysiological tissues. Importantly, the 3D microphysiological tissues are grown on optically clear platforms that offer non-invasive and non-destructive image acquisition with subcellular resolution in real time. Such systems offer a new paradigm for high-throughput drug screening and will significantly improve the efficiency of identifying new drugs for cancer treatment that minimize cardiac and bone marrow toxicity
Tumor-on-chip modeling of organ-specific cancer and metastasis
Every year, cancer claims millions of lives around the globe. Unfortunately, model systems that accurately mimic human oncology - a requirement for the development of more effective therapies for these patients - remain elusive. Tumor development is an organ-specific process that involves modification of existing tissue features, recruitment of other cell types, and eventual metastasis to distant organs. Recently, tissue engineered microfluidic devices have emerged as a powerful in vitro tool to model human physiology and pathology with organ-specificity. These organ-on-chip platforms consist of cells cultured in 3D hydrogels and offer precise control over geometry, biological components, and physiochemical properties. Here, we review progress towards organ-specific microfluidic models of the primary and metastatic tumor microenvironments. Despite the field\u27s infancy, these tumor-on-chip models have enabled discoveries about cancer immunobiology and response to therapy. Future work should focus on the development of autologous or multi-organ systems and inclusion of the immune system
Advances in modeling the immune microenvironment of colorectal cancer
Colorectal cancer (CRC) is the third most common cancer and second leading cause of cancer-related death in the US. CRC frequently metastasizes to the liver and these patients have a particularly poor prognosis. The infiltration of immune cells into CRC tumors and liver metastases accurately predicts disease progression and patient survival. Despite the evident influence of immune cells in the CRC tumor microenvironment (TME), efforts to identify immunotherapies for CRC patients have been limited. Here, we argue that preclinical model systems that recapitulate key features of the tumor microenvironment-including tumor, stromal, and immune cells; the extracellular matrix; and the vasculature-are crucial for studies of immunity in the CRC TME and the utility of immunotherapies for CRC patients. We briefly review the discoveries, advantages, and disadvantages of curren
An iPS-derived in vitro model of human atrial conduction
Atrial fibrillation (AF) is the most common arrhythmia in the United States, affecting approximately 1 in 10 adults, and its prevalence is expected to rise as the population ages. Treatment options for AF are limited; moreover, the development of new treatments is hindered by limited (1) knowledge regarding human atrial electrophysiological endpoints (e.g., conduction velocity [CV]) and (2) accurate experimental models. Here, we measured the CV and refractory period, and subsequently calculated the conduction wavelength, in vivo (four subjects with AF and four controls), and ex vivo (atrial slices from human hearts). Then, we created an in vitro model of human atrial conduction using induced pluripotent stem (iPS) cells. This model consisted of iPS-derived human atrial cardiomyocytes plated onto a micropatterned linear 1D spiral design of Matrigel. The CV (34-41 cm/s) of the in vitro model was nearly five times faster than 2D controls (7-9 cm/s) and similar to in vivo (40-64 cm/s) and ex vivo (28-51 cm/s) measurements. Our iPS-derived in vitro model recapitulates key features of in vivo atrial conduction and may be a useful methodology to enhance our understanding of AF and model patient-specific disease
Recommended from our members
Design considerations to minimize the impact of drug absorption in polymer-based organ-on-a-chip platforms.
Biocompatible polymers, such as polydimethylsiloxane (PDMS), are the materials of choice for creating organ-on-a-chip microfluidic platforms. Desirable qualities include ease of fabrication, optical clarity, and hydrophobicity, the latter of which facilitates oxygen transport to encased cells. An emerging and important application of organ-on-a-chip technology is drug discovery; however, a potential issue for polymer-based microfluidic devices has been highlighted by recent studies with PDMS, which have demonstrated absorption (and thus loss) of hydrophobic drugs into PDMS under certain experimental conditions. Absorption of drug in the polymer can also lead to undesirable transfer of drug between adjacent microfluidic lines. Given the benefits of polymers, it is essential to develop a comprehensive understanding of drug absorption. In this study, we considered convection, dissolution, and diffusion of a drug within a polymer-based microfluidic device to characterize the dynamics of drug loss in a quantitative manner. We solved Ficks 2nd law of diffusion (unsteady diffusion-convection) by finite element analysis in COMSOL®, and experimentally validated the numerical model for loss of three hydrophobic molecules (rhodamine B, cyanine NHS ester, and paclitaxel) in PDMS. Drug loss, as well as the unintended mixing of drugs by adjacent microfluidic channels, depends strongly on platform design parameters, experimental conditions, and the physico-chemical properties of the drug, and can be captured in a simple quantitate relationship that employs four scalable dimensionless numbers. This simple quantitative framework can be used in the design of a wide range of polymer-based microfluidic devices to minimize the impact of drug absorption
Mac-2 Binding Protein Is a Novel E-Selectin Ligand Expressed by Breast Cancer Cells
<div><p>Hematogenous metastasis involves the adhesion of circulating tumor cells to vascular endothelium of the secondary site. We hypothesized that breast cancer cell adhesion is mediated by interaction of endothelial E-selectin with its glycoprotein counter-receptor(s) expressed on breast cancer cells. At a hematogenous wall shear rate, ZR-75-1 breast cancer cells specifically adhered to E-selectin expressing human umbilical vein endothelial cells when tested in parallel plate flow chamber adhesion assays. Consistent with their E-selectin ligand activity, ZR-75-1 cells expressed flow cytometrically detectable epitopes of HECA-452 mAb, which recognizes high efficiency E-selectin ligands typified by sialofucosylated moieties. Multiple E-selectin reactive proteins expressed by ZR-75-1 cells were revealed by immunoprecipitation with E-selectin chimera (E-Ig chimera) followed by Western blotting. Mass spectrometry analysis of the 72 kDa protein, which exhibited the most prominent E-selectin ligand activity, corresponded to Mac-2 binding protein (Mac-2BP), a heretofore unidentified E-selectin ligand. Immunoprecipitated Mac-2BP expressed sialofucosylated epitopes and possessed E-selectin ligand activity when tested by Western blot analysis using HECA-452 mAb and E-Ig chimera, respectively, demonstrating that Mac-2BP is a novel high efficiency E-selectin ligand. Furthermore, silencing the expression of Mac-2BP from ZR-75-1 cells by shRNA markedly reduced their adhesion to E-selectin expressing cells under physiological flow conditions, confirming the functional E-selectin ligand activity of Mac-2BP on intact cells. In addition to ZR-75-1 cells, several other E-selectin ligand positive breast cancer cell lines expressed Mac-2BP as detected by Western blot and flow cytometry, suggesting that Mac-2BP may be an E-selectin ligand in a variety of breast cancer types. Further, invasive breast carcinoma tissue showed co-localized expression of Mac-2BP and HECA-452 antigens by fluorescence microscopy, underscoring the possible role of Mac-2BP as an E-selectin ligand. In summary, breast cancer cells express Mac-2BP as a novel E-selectin ligand, potentially revealing a new prognostic and therapeutic target for breast cancer.</p> </div
Several breast cancer cell lines express Mac-2BP.
<p>(<b>A</b>) Lysates of 2×10<sup>6</sup> cells obtained from a variety of breast cancer cell lines were subjected to Western blot analysis with anti-Mac-2BP pAb. β-actin staining was used as the loading control. (<b>B</b>) Breast cancer cells were surface labeled with anti-Mac-2BP pAb and analyzed by flow cytometry. Open curve shows isotype, and filled curve shows specific antibody. (<b>C</b>) Immunoprecipitates from ZR-75-1 or BT-20 cell lysate (5 × 10<sup>6</sup> cells) by anti-Mac-2BP mAb were subjected to Western blotting with E-Ig chimera.</p
Mac-2BP silencing of ZR-75-1 cells reduces their adhesion to E-selectin.
<p>(<b>A</b>) Vector or Mac-2BP silenced cells were surface labeled with anti-Mac-2BP pAb and analyzed by flow cytometry. The data are represented as mean fluorescence intensity ± SE for n = 5 independent experiments. *P<0.05 with respect to vector. (<b>B</b>) Vector or Mac-2BP silenced cells (10<sup>6</sup>/ml) were perfused over CHO-E cells for 4 min at a wall shear rate of 80 s<sup>−1</sup> and the number of adhering cancer cells were counted. Data are mean ± SE for n = 5 independent experiments. *P<0.05 with respect to vector. (<b>C</b>) The rolling velocity of vector and silenced cells over CHO-E cells was determined at a wall shear rate of 80 s<sup>−1</sup>. Data are mean ± SE for n = 10 cells. *P<0.05 with respect to vector. (<b>D</b>) Vector or silenced cells (10<sup>6</sup>/ml) were perfused over CHO-E cells for 4 min at a wall shear rate of 80 s<sup>−1</sup> and then the shear rate was doubled in 30 s time intervals. Data are mean ± SE for n = 5 independent experiments. *P<0.05 with respect to vector.</p
Identification of a novel protein, Mac-2BP, as an E-selectin ligand.
<p>(<b>A</b>) The steps followed for identification of the E-selectin reactive protein. Biotinylated ZR-75-1 cells (5 × 10<sup>6</sup>) were lysed and immunoprecipitated using E-Ig chimera. Immunoprecipitates were resolved by SDS-PAGE and subsequently blotted with streptavidin-AP. The intensity histogram was obtained by analysis of digitalized image using Image Lab software. (<b>B</b>) Lysate from ZR-75-1 cells (2 × 10<sup>6</sup>) was subjected to Western blotting with anti-Mac-2BP pAb. Immunoprecipitates from ZR-75-1 cell lysate (5 × 10<sup>6</sup> cells) by anti-Mac-2BP mAb were Western blotted with E-Ig chimera or HECA-452 mAb.</p